COVID-19 Show message

Skip to content

Principal Investigator


B.S., Yale College, 1974, Molec. Biophysics & Biochemistry (1970 - 1974)
M.D., Johns Hopkins School of Medicine, 1978 (1974 - 1978)
Ph.D., Pharmacology, Johns Hopkins School of Medicine, 1981 (1976 - 1980)
Nuclear Medicine, six-month training for Authorized User (10 CFR 35) of radiopharmaceuticals in human subjects (1995)

1980-1984 Resident in Psychiatry, Yale University (1980 - 1984)
1984-1990 Assistant Professor, Dept. Psychiatry, Yale University
1990-1994 Associate Professor, Yale Dept. Psychiatry
1994-2001 Appointment with tenure, Yale University
1996-2001 Professor of Psychiatry and Pharmacology, Yale University
2001- Chief, Molecular Imaging Branch, NIMH

Research Interests

Working in close collaboration with the radiochemistry laboratory of Dr. Victor Pike, my laboratory uses in vivo imaging to evaluate novel positron emission tomographic (PET) radioligands, first in animals, then in healthy human subjects, and finally in patients. My laboratory has multidisciplinary expertise in pharmacology, animal experimentation, clinical neuroscience, digital image analysis, and human evaluation of investigational radiopharmaceuticals. In addition to traditional receptor targets, we use radiolabeled probes for in vivo imaging of neuroinflammation (including translocator protein, COX-1, and COX-2) and intracellular signal transduction (eg, cAMP phosphodiesterase). A major goal of the lab is to use these radioligands to facilitate clinical trials of novel therapeutics. Such trials are in the early planning stages with regard to phosphodiesterase-4 (PDE4) and neuroinflammation in depression.

Selected Publications

11C-ER176, a Radioligand for 18-kDa Translocator Protein, Has Adequate Sensitivity to Robustly Image All Three Affinity Genotypes in Human Brain. Ikawa M, Lohith TG, Shrestha S, Telu S, Zoghbi SS, Castellano S, Taliani S, Da Settimo F, Fujita M, Pike VW, Innis RB, Biomarkers Consortium Radioligand Project Team. J Nucl Med. 2017;58(2):320-325. PMID: 27856631.

cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor. Fujita M, Richards EM, Niciu MJ, Ionescu DF, Zoghbi SS, Hong J, Telu S, Hines CS, Pike VW, Zarate CA, Innis RB. Mol Psychiatry. 2017;22(5):754-759. PMID: 27725657.

(11)C-PBR28 binding to translocator protein increases with progression of Alzheimer’ disease. Kreisl WC, Lyoo CH, Liow JS, Wei M, Snow J, Page E, Jenko KJ, Morse CL, Zoghbi SS, Pike VW, Turner RS, Innis RB. Neurobiol Aging. 2016;44:53-61. PMID: 27318133.

Fluoxetine administered to juvenile monkeys: effects on the serotonin transporter and behavior. Shrestha SS, Nelson EE, Liow JS, Gladding R, Lyoo CH, Noble PL, Morse C, Henter ID, Kruger J, Zhang B, Suomi SJ, Svenningsson P, Pike VW, Winslow JT, Leibenluft E, Pine DS, Innis RB. Am J Psychiatry. 2014;171(3):323-31 PMID: 24480874.

A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. Kreisl WC, Jenko KJ, Hines CS, Lyoo CH, Corona W, Morse CL, Zoghbi SS, Hyde T, Kleinman JE, Pike VW, McMahon FJ, Innis RB, Biomarkers Consortium PET Radioligand Project Team. J Cereb Blood Flow Metab. 2013;33(1):53-8. PMID: 22968319.

Magnuson Clinical Center, Room B1D43J, MSC 1026

Phone: +1 301 594 1368
Fax: +1 301 480 3610